These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23603933)

  • 21. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity.
    Fitzjohn SM; Bortolotto ZA; Palmer MJ; Doherty AJ; Ornstein PL; Schoepp DD; Kingston AE; Lodge D; Collingridge GL
    Neuropharmacology; 1998 Dec; 37(12):1445-58. PubMed ID: 9886667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.
    Caraci F; Molinaro G; Battaglia G; Giuffrida ML; Riozzi B; Traficante A; Bruno V; Cannella M; Merlo S; Wang X; Heinz BA; Nisenbaum ES; Britton TC; Drago F; Sortino MA; Copani A; Nicoletti F
    Mol Pharmacol; 2011 Mar; 79(3):618-26. PubMed ID: 21159998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J; Monn JA; Schoepp DD
    J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex.
    Okamura N; Hashimoto K; Shimizu E; Koike K; Ohgake S; Koizumi H; Kumakiri C; Komatsu N; Iyo M
    Brain Res; 2003 Nov; 992(1):114-9. PubMed ID: 14604779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
    Dominguez C; Prieto L; Valli MJ; Massey SM; Bures M; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD; Monn JA
    J Med Chem; 2005 May; 48(10):3605-12. PubMed ID: 15887967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation.
    Zhang C; Marek GJ
    J Pharmacol Exp Ther; 2007 Jan; 320(1):437-47. PubMed ID: 17021259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
    Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
    J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells.
    D'Onofrio M; Arcella A; Bruno V; Ngomba RT; Battaglia G; Lombari V; Ragona G; Calogero A; Nicoletti F
    J Neurochem; 2003 Mar; 84(6):1288-95. PubMed ID: 12614329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.
    Amitai N; Markou A
    Eur J Pharmacol; 2010 Aug; 639(1-3):67-80. PubMed ID: 20371228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268.
    Sutton LP; Rushlow WJ
    J Neurochem; 2011 Jun; 117(6):973-83. PubMed ID: 21477044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.
    Lavreysen H; Wouters R; Bischoff F; Nóbrega Pereira S; Langlois X; Blokland S; Somers M; Dillen L; Lesage AS
    Neuropharmacology; 2004 Dec; 47(7):961-72. PubMed ID: 15555631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats.
    Swanson CJ; Schoepp DD
    J Pharmacol Exp Ther; 2002 Dec; 303(3):919-27. PubMed ID: 12438510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
    Lorrain DS; Schaffhauser H; Campbell UC; Baccei CS; Correa LD; Rowe B; Rodriguez DE; Anderson JJ; Varney MA; Pinkerton AB; Vernier JM; Bristow LJ
    Neuropsychopharmacology; 2003 Sep; 28(9):1622-32. PubMed ID: 12825094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
    Monn JA; Massey SM; Valli MJ; Henry SS; Stephenson GA; Bures M; Hérin M; Catlow J; Giera D; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD
    J Med Chem; 2007 Jan; 50(2):233-40. PubMed ID: 17228865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.
    Carter K; Dickerson J; Schoepp DD; Reilly M; Herring N; Williams J; Sallee FR; Sharp JW; Sharp FR
    Neuropharmacology; 2004 Dec; 47(8):1135-45. PubMed ID: 15567423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    Liechti ME; Markou A
    Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.
    Cartmell J; Monn JA; Schoepp DD
    Eur J Pharmacol; 2000 Jul; 400(2-3):221-4. PubMed ID: 10988337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.